---
title: CytRx Initiates Phase 2 Clinical Trial with INNO-206 in Pancreatic Cancer - TD2 Precision Oncology
description: Daniel Von Hoff, M.D., Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGEN) in Phoenix will serve as the clinical trial’s principal investigator while TGen’s subsidiary, TGen Drug Development, manages this Phase 2 clinical trial on behalf of CytRx. Dr. Von Hoff was a former member of the National Cancer Advisory Board and the FDA’s Oncology Drug […]
---

[News & Events - TD2 Precision Oncology ](https://td2inc.com/news-events)

# [CytRx Initiates Phase 2 Clinical Trial with INNO-206 in Pancreatic Cancer - TD2 Precision Oncology](https://td2inc.com/news-events/cytrx-initiates-phase-2-clinical-trial-with-inno-206-in-pancreatic-cancer)

 Written by [TD2](https://td2inc.com/news-events/author/td2) | May 31, 2012 4:30:00 PM

Daniel Von Hoff, M.D., Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGEN) in Phoenix will serve as the clinical trial’s principal investigator while TGen’s subsidiary, TGen Drug Development, manages this Phase 2 clinical trial on behalf of CytRx. Dr. Von Hoff was a former member of the National Cancer Advisory Board and the FDA’s Oncology Drug Advisory Committee, and former President of the American Association for Cancer Research. He currently co-directs the Pancreatic Cancer Dream Team, one of five Stand Up 2 Cancer teams comprised of renowned scientists working collaboratively on innovation, acceleration, targeted therapy and translational research in several major cancers..."

for full press release go [here](http://www.businesswire.com/news/home/20120426005126/en/CytRx-Initiates-Phase-2-Clinical-Trial-INNO-206).

[View full post](https://td2inc.com/news-events/cytrx-initiates-phase-2-clinical-trial-with-inno-206-in-pancreatic-cancer)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "TD2"
  },
  "dateModified" : "2024-04-01T02:26:07.255Z",
  "datePublished" : "2012-05-31T16:30:00Z",
  "headline" : "CytRx Initiates Phase 2 Clinical Trial with INNO-206 in Pancreatic Cancer",
  "image" : {
    "@type" : "ImageObject",
    "height" : 630,
    "url" : "https://22578525.fs1.hubspotusercontent-na1.net/hubfs/22578525/Assets/Images/og-news-events.jpg",
    "width" : 1200
  },
  "mainEntityOfPage" : "https://td2inc.com/news-events/cytrx-initiates-phase-2-clinical-trial-with-inno-206-in-pancreatic-cancer",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "News & Events - TD2 Precision Oncology"
  }
}
```